Table 4.
Comparison of the methods of treatment in children with IgAN in Group A and B.
| Treatment | Gr.A (GRF≥ 90 mL/min) | Gr.B (GFR < 90 mL/min) | p |
|---|---|---|---|
| Without medication | 2 (6.7%) | 2 (8.3%) | NS |
| R only | 8 (26.7%) | 12 (50%) | NS |
| P+R | 8 (26.7%) | 3 (12.5%) | NS |
| P+R or I+P+R | 26 (86.6%) | 15 (62.5%) | <0.05 |
| I (Aza/Cyc/CsA/MMF+P+R) | 16 (53.3%) | 10 (41.7%) | NS |
| Aza+P+R | 10 (33.3%) | 5 (20.8%) | NS |
| Cyc+P+R | 5 (16.7%) | 0 | <0.05 |
| CsA+P+R | 1 (3.3%) | 3 (12.5%) | NS |
| MMF+P+R | 0 | 2 (8.3%) | <0.05 |
R—renal protection; P—prednisone; I—immunosuppressive therapy; Aza—azathioprine; Cyc—cyclophosphamide-; CsA—cyclosporine; MMF—mycophenolate mofetil; GFR—glomerular filtration rate; NS—not significant.